FOLH1 and prostate cancer: We then replaced the acetyl group of [68Ga]Ga-DOTA-AmBz-MVK(Ac)-OH with the pharmacophore of HTK01166 (Figure 2), a peptidomimetic targeting the prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer [15].